Perrigo Animal Health

Perrigo Animal Health
Share

Perrigo Animal Health

 •  August 21

DUBLIN, Aug. 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug Administration for the store brand OTC equivalent of Nexium® 24HR (esomeprazole magnesium) capsules. The company also announced that it has reached a settlement of patent litigation with...

Perrigo Animal Health

 •  June 21

DUBLIN, June 21, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality Affordable Healthcare Products®", today announced that the Company's Board of Directors has retained Spencer Stuart, a leading global executive search and leadership advisory firm, to assist with the search for the Company's next...

DUBLIN, May 8, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced the appointment of Rolf A. Classon and Adriana Karaboutis to the Company's Board of Directors. Pursuant to the agreement with Starboard Value LP ("Starboard") announced on February 7, 2017, Starboard recommended that Mr. Classon and Ms. Karaboutis be...

Perrigo Animal Health

 •  March 7

DUBLIN, March 7, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of Quality, Affordable Healthcare Products®, today commented, "As previously discussed, in connection with a review for the announced sale of the Tysabri® royalty stream and evaluation procedures associated with Accounting Standards Codification® 606,...

Perrigo Animal Health

 •  January 10

DUBLIN, Jan. 10, 2017 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has changed its reporting segments to better align with the Company's organizational structure. Beginning with the fourth quarter of calendar year 2016, the Company's new reporting segments are: Consumer Healthcare Americas – Comprises the legacy...

Perrigo Animal Health

 •  December 22, 2016

DUBLIN, Dec. 22, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that CEO John T. Hendrickson will present at the J.P. Morgan Global Healthcare Conference at 11:00 AM EST on Tuesday, January 10, 2017 at the Westin St. Francis Hotel in San Francisco, California. Interested parties can access the presentation webcast at...

Perrigo Animal Health

 •  December 8, 2016

DUBLIN, Dec. 8, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced its intention to restructure the Branded Consumer Healthcare's ("BCH") Omega Pharma Belgium business (which includes Omega Pharma Belgium NV, Etixx NV and Biover NV), located in Nazareth, Venecoweg 26 (Belgium) to improve the financial profile and enhance...

Perrigo Animal Health

 •  November 10, 2016

DUBLIN, Nov. 10, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that as part of its ongoing business portfolio review, the Company will review strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug Tysabri® (natalizumab). Perrigo's CEO John T. Hendrickson stated, "We...

Perrigo Animal Health

 •  November 10, 2016

DUBLIN, Nov. 10, 2016 /PRNewswire/ -- Delivered third quarter GAAP ("reported") net sales of $1.4 billion and non-GAAP ("adjusted") net sales of $1.3 billion, excluding sales of $22 million from held-for-sale businesses* Delivered third quarter reported net loss of $1.3 billion and reported diluted loss per share of $8.76, driven by goodwill...

Perrigo Animal Health

 •  September 27, 2016

DUBLIN, Sept. 27, 2016 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced an exclusive licensing agreement with Highland Pharmaceuticals, LLC for its Tarex® methamphetamine ("meth") blocking technology and the distribution rights of Zephrex-D® (pseudoephedrine HCI 30 mg). Zephrex-D® was developed using the Tarex® technology and...